Synergistic anti-inflammatory compositions comprising
The present invention discloses synergistic nutraceutical or pharmaceutical or dietary supplement anti-inflammatory compositions comprising therapeutically effective combination of an extract selectively enriched in 3-O-acetyl-1 1-keto-β-boswellic acid (AKBA) derived from Boswellia serrata and Boswellia serrata non-acidic resin extract (BNRE). The composition(s) can be used to prevent, control and treat inflammation and several inflammatory related diseases including asthma, osteoarthritis, rheumatoid arthritis, endothelial dysfunction and the like. The invention further discloses the amelioration of pro-inflammatory biomarker proteins or molecules, whose expression/production is altered during inflammatory diseases.
1. An anti-inflammatory composition, comprising a therapeutically effective amount of a combination of:
from 10% to 90% by weight of the combination of a Boswellia serrata extract selectively enriched in 3-O-acetyl-11-keto-β-boswellic acid (AKBA); and
from 10% to 90% by weight of the combination of a Boswellia serrata resin non-acidic, water-immiscible organic solvent extract (BNRE) obtained by selectively removing acidic compounds from a Boswellia serrata gum resin extract.
2. The anti-inflammatory composition of claim 1 , wherein the Boswellia serrata resin non-acidic, water-immiscible organic solvent extract comprises at least three compounds selected from the group consisting of guiol, nephthenol, serratol, diterpene X, lupeol, olean-12-ene-3β-ol, olean-12-ene-3α-ol, lanosta-8,24-diene-3α-ol and urs-12-ene-3α-ol.
3. The anti-inflammatory composition of claim 1 , wherein the selectively enriched Boswellia serrata extract contains AKBA in a concentration of 10% to 100% by weight.
4. The anti-inflammatory composition of claim 1 , wherein the selectively enriched Boswellia serrata extract contains AKBA in a concentration of 25% to 95% by weight.
5. The anti-inflammatory composition of claim 1 , wherein the selectively enriched Boswellia serrata extract contains AKBA in a concentration of 25% to 45% by weight.
6. The anti-inflammatory composition of claim 1 , wherein said obtaining the Boswellia serrata non-acidic resin extract (BNRE) comprises:
extraction of gum resin of Boswellia serrata with a water immiscible organic solvent,
filtering the extract to remove undissolved resin material to provide an organic solvent extract;
washing the organic solvent extract with an aqueous alkali solution to produce an organic layer; and
evaporating organic solvent from the organic layer to obtain an oily residue; and
removing volatile compounds from the oily residue under high vacuum and high temperature to obtain the Boswellia serrata resin non-acidic, water-immiscible organic solvent (BNRE).
7. The anti-inflammatory composition of claim 1 , wherein the composition further comprises at least one excipient, diluent, or additive.
8. The anti-inflammatory composition of claim 7 , wherein the at least one excipient, diluent, or additive is selected from the group consisting of distilled water; saline; aqueous glucose solution; ethanol; propylene glycol; polyethylene glycol; an oily carrier selected from the group consisting of animal and vegetable oils, white soft paraffin, paraffin, and wax; glucose; fructose; sucrose; maltose; dextrin; microcrystalline cellulose; calcium stearate; magnesium stearate; sorbitol; stevioside; corn syrup; lactose; citric acid; tartaric acid; malic acid; succinic acid; lactic acid; L-ascorbic acid; dl-alpha-tocopherol; glycerin; glycerin fatty ester; poly glycerin fatty ester; sucrose fatty ester; sorbitan fatty ester; propylene glycol fatty ester; acacia; carrageenan; casein; gelatin; pectin; agar; nicotinamide; calcium pantothenate; amino acids; calcium salts; pigments; flavors; preservatives; and a mixture thereof.
9. The anti-inflammatory composition of claim 1 , further comprising at least one pharmacologically acceptable antioxidant, adaptogen, anti-inflammatory agent, anti-diabetic agent, anti-obese agent, or anti-atherosclerotic agent.
10. A dosage form for oral administration, comprising the anti-inflammatory composition of claim 1 , wherein the dosage form is a tablet, a capsule, a pill, granules, a powder, an emulsion, a suspension, a syrup, a pellet, or a dietary supplement.
11. A dosage form for transdermal administration, comprising the anti-inflammatory composition of claim 1 , wherein the dosage form is a transdermal patch, a cream, a gel, or an ointment.
12. A dosage form for parenteral administration, comprising the anti-inflammatory composition of claim 1 , wherein the dosage form is an infusion solution, an injection solution, an enema, drops, or a suppository.
13. A dosage form comprising the anti-inflammatory composition of claim 1 , wherein the dosage form is adapted for administration by inhalation.
14. A method for treating inflammation, comprising:
administering to a subject in need thereof a therapeutically effective amount of the composition of claim 1 , optionally in combination with at least one of:
an excipient, diluent, or additive; and
a pharmacologically acceptable antioxidant, adaptogen, anti-inflammatory agent, anti-diabetic agent, anti-obese agent, or anti-atherosclerotic agent.